Searched for
CIPLA GLOBAL
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- India among Asia-Pacific's most AI-ready healthcare markets as demand for coordinated care rises: BainIndia is emerging as one of the most AI-ready healthcare markets in the Asia-Pacific region, with a growing number of consumers using gener...
- Global drugmakers rush to boost US presence as tariff threat loomsGlobal drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...
- Nifty in control of FIIs? The unlucky 13 bluechips facing the hardest institutional selloffForeign investors have significantly reduced holdings in many Nifty companies since September 2024. This has impacted top blue-chip stocks,...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Q4 earnings review: Motilal Oswal highlights broad-based beat on estimates, lists 6 sectors that exceeded expectationsMotilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Geopolitical stability will decide market’s next move: Sandip SabharwalIndian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...
- Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap playsIndian equity markets show a mixed but improving consumption trend, with selective FMCG and premium retail outperforming. Page Industries i...
- India Inc's foreign investments more than double in AprilIndian companies significantly boosted overseas investments in April. Direct investments surged to $3.37 billion, more than doubling from M...
- Rising bond yields, oil prices keeping markets on edge; selective bets still emerging: Pankaj PandeyGlobal markets are under pressure due to rising bond yields and geopolitical tensions. Higher crude oil prices are a key concern, potential...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Cipla Q4 net profit slumps 55% YoY to Rs 555 crore, full-year PAT down 26%Pharma major Cipla announced a significant 55% drop in its net profit for the March quarter. Total income also saw a 3% decrease. For the f...
- Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividendCipla's fourth-quarter net profit saw a significant drop of 55 percent year-on-year. For the full financial year, the company's profit also...
- Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...
- Stocks in news: Airtel, Tata Motors, Dr Reddy's, NTPC, Dixon TechnologiesMarkets faced selling pressure on Tuesday due to weak global cues and macroeconomic concerns, with the Nifty approaching support at 23,150....
- LIC’s $2 billion contrarian bet: 10 stocks the DII giant bought while the market bledLife Insurance Corporation of India invested nearly $2 billion in 10 stocks during the March quarter's market fall. LIC bought shares in co...
Load More
